局限期尤文肉瘤放疗疗效异质性:EURO-E.W.I.N.G. 99与Ewing 2008试验二次分析
该研究基于EURO-E.W.I.N.G. 99和Ewing 2008试验中1501例局限期尤文肉瘤患者,采用因果生存森林预测联合局部治疗(放疗+手术)对比单纯手术的个体化治疗效果。结果显示疗效异质性显著,19.4%患者从联合治疗中获得有临床意义的获益(5年EFS延长≥6个月),预测获益最少四分位患者风险增加53%,获益最多四分位风险降低40%。手术切缘状态在联合治疗患者中与治疗获益无关。
要点
- 联合局部治疗对比单纯手术的疗效存在显著异质性,仅19.4%患者获得有临床意义的获益。
- 预测获益最少四分位患者任何事件风险增加53%(HR 1.53, 95%CI 1.06-2.20, p=0.02)。
- 预测获益最多四分位患者风险降低40%(HR 0.60, 95%CI 0.42-0.85, p=0.004)。
核心结论
- 预测的个体化治疗效果有助于识别从联合局部治疗中获益的局限期尤文肉瘤患者。
- 非广泛手术切缘患者未从联合治疗中获益,挑战了基于传统亚组分析的决策实践。
研究设计与样本
- 研究为EURO-E.W.I.N.G. 99和Ewing 2008试验的二次分析,纳入1501例局限期尤文肉瘤患者。
- 采用因果生存森林预测个体化治疗效果,并通过重复k折交叉验证进行验证。
- 使用Shapley加性解释分析评估个体化治疗效果的预测因子。
主要发现
- 1501例患者中719例接受联合治疗,782例接受单纯手术。
- 预测的个体化治疗效果显示显著异质性(范围:-0.7至1.0年)。
- 19.4%患者从联合治疗中获得有临床意义的获益(5年EFS增加≥6个月)。
- 预测获益最少四分位患者任何事件风险增加53%(HR 1.53, 95%CI 1.06-2.20, p=0.02)。
- 预测获益最多四分位患者风险降低40%(HR 0.60, 95%CI 0.42-0.85, p=0.004)。
临床怎么用
- 预测的个体化治疗效果可用于辅助识别可能从联合局部治疗中获益的局限期尤文肉瘤患者。
- 手术切缘状态不应单独作为联合局部治疗决策的依据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Standard Ewing sarcoma treatment includes chemotherapy and local therapy. Previous studies found no average treatment effect of combined local therapy (radiotherapy and surgery) versus surgery alone, leaving it unclear which patients benefit from combined therapy. METHODS: We analysed patients with localized Ewing sarcoma from the EURO-E.W.I.N.G. 99 and Ewing 2008 trials. Using causal survival forests validated through repeated k-fold cross-validation, we predicted individualized treatment effects (ITEs) for 5-year event-free survival (5y EFS) comparing combined therapy to surgery alone. We developed a personalized treatment rule and evaluated ITE predictors using Shapley additive explanations analysis. RESULTS: Of 1501 patients, 719 received combination therapy and 782 surgery alone. Predicted ITEs showed substantial heterogeneity (range: -0.7-1.0 years). We found that 19.4% of patients derived clinically meaningful benefit (5y EFS increase ≥6 months) from combined therapy. In the quartile predicted to benefit least, hazards of any event were increased by 53% (HR 1.53, 95% CI 1.06-2.20, p = 0.02). Conversely, in the quartile predicted to benefit most, hazards were reduced by 40% (HR 0.60, 95% CI 0.42-0.85, p = 0.004). In patients undergoing combined treatment, surgical margin status was not associated with treatment benefit. A simulation analysis showed that applying our treatment strategy could improve EFS. DISCUSSION: Our predicted ITEs can help identify patients benefiting from combined therapy. The finding that patients with non-wide surgical margins did not benefit from combined therapy challenges current decision-making practices based on traditional subgroup analyses.
引用
- Heesen P, Feuerriegel S, Ciobanu-Caraus O, et al. Treatment effect heterogeneity of radiotherapy in localized Ewing sarcoma: A secondary analysis of the EURO-E.W.I.N.G. 99 and Ewing 2008 trial. Eur J Cancer. 2026. PMID: 42218103. doi:10.1016/j.ejca.2026.116825
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。